{
  "drug_name": "Neomycin",
  "usage_and_dosing": {
    "description": "Neomycin is an oral aminoglycoside used as bowel preparation pre-operatively for resectional GI surgery and for treatment of hepatic encephalopathy. Systemic absorption can occur and lead to ototoxicity, neurotoxicity or nephrotoxicity (Black Box Warning). Low concentration in non-prescription topical creams and ointments. Active in vitro vs. staphylococci and most aerobic Gram-negative bacteria; resistant to streptococci and Gram-positive bacilli",
    "adult_dose": [
      {
        "route": "Bowel preparation, pre-GI surgery",
        "dose": "1 gm at 1, 2 and 11 pm on day preceding surgery + Erythromycin 1 gm po at the same times + mechanical cleansing"
      },
      {
        "route": "Hepatic encephalopathy",
        "dose": "500-2000 mg q6-8h for 5-6 days; seek safer alternative for longer use"
      }
    ],
    "pediatric_dose": [
      {
        "age": ">28 Days",
        "dose": "HE: 50-100 mg/kg/day (divided q6-8hr) x5-6 days. Seek safer alternative for longer use."
      }
    ]
  },
  "renal_adjustment": {
    "half_life_normal_function": "2-3 hrs",
    "half_life_esrd": "30-70 hrs",
    "dose_renal_function_normal": "1 gm po x3 (prior to surgery)",
    "crcl_or_egfr": "No dosage adjustment for renal impairment",
    "hemodialysis": "No dosage adjustment",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment": "No dosage adjustment",
    "moderate_impairment": "No dosage adjustment",
    "severe_impairment": "No dosage adjustment"
  },
  "adverse_effects": [
    "No significant adverse effects"
  ],
  "antimicrobial_spectrum": {
    "preferred": [
      "Aerobic gram-negative bacilli"
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "No data",
    "pharmaceutical_preparations": "Tab (500 mg)",
    "food_rec_po_drugs": "Tab + food",
    "oral_absorption": "<3%",
    "tmax": "No data",
    "peak_serum_conc": "No data",
    "peak_urine_conc": "No data",
    "protein_binding": "No data",
    "volume_of_distribution": "No data",
    "avg_serum_t1_2": "No data",
    "elimination": "Negligible absorption",
    "bile_penetration": "No data",
    "csf_blood": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc": "No data"
  },
  "major_drug_interactions": [
    "None significant"
  ],
  "comments": [
    "Avoid concomitant agents and factors that enhance oto-, neuro- or nephrotoxicity",
    "For treatment of hepatic encephalopathy, considered an alternative agent; safer agents are available (Hepatology 60: 715, 2014).",
    "Review: Clin Micro Review 30(3): 827, 2017."
  ]
}